<?xml version='1.0' encoding='utf-8'?>
<document id="17217399"><sentence text="Lack of inhibitory effects of several fluoroquinolones on cytochrome P-450 3A activities at clinical dosage in dogs."><entity charOffset="38-54" id="DDI-PubMed.17217399.s1.e0" text="fluoroquinolones" /></sentence><sentence text="Inhibitory effects of several fluoroquinolones (FQs) on liver CYP3A activities were examined by in vitro and in vivo tests in dogs"><entity charOffset="30-46" id="DDI-PubMed.17217399.s2.e0" text="fluoroquinolones" /></sentence><sentence text=" Midazolam (MDZ) hydroxylation rate was used to determine the CYP3A activities in liver microsomes"><entity charOffset="1-10" id="DDI-PubMed.17217399.s3.e0" text="Midazolam" /><entity charOffset="12-15" id="DDI-PubMed.17217399.s3.e1" text="MDZ" /><pair ddi="false" e1="DDI-PubMed.17217399.s3.e0" e2="DDI-PubMed.17217399.s3.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s3.e0" e2="DDI-PubMed.17217399.s3.e1" /></sentence><sentence text=" Enrofloxacin (EFX), ofloxacin (OFX) orbifloxacin (OBFX) and ciprofloxacin (CFX) were tested"><entity charOffset="1-13" id="DDI-PubMed.17217399.s4.e0" text="Enrofloxacin" /><entity charOffset="15-18" id="DDI-PubMed.17217399.s4.e1" text="EFX" /><entity charOffset="21-30" id="DDI-PubMed.17217399.s4.e2" text="ofloxacin" /><entity charOffset="32-35" id="DDI-PubMed.17217399.s4.e3" text="OFX" /><entity charOffset="37-49" id="DDI-PubMed.17217399.s4.e4" text="orbifloxacin" /><entity charOffset="51-55" id="DDI-PubMed.17217399.s4.e5" text="OBFX" /><entity charOffset="61-74" id="DDI-PubMed.17217399.s4.e6" text="ciprofloxacin" /><entity charOffset="76-79" id="DDI-PubMed.17217399.s4.e7" text="CFX" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e0" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e1" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e2" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e2" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e3" e2="DDI-PubMed.17217399.s4.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e3" e2="DDI-PubMed.17217399.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e3" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e3" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e3" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e4" e2="DDI-PubMed.17217399.s4.e4" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e4" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e4" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e4" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e5" e2="DDI-PubMed.17217399.s4.e5" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e5" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e5" e2="DDI-PubMed.17217399.s4.e7" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e6" e2="DDI-PubMed.17217399.s4.e6" /><pair ddi="false" e1="DDI-PubMed.17217399.s4.e6" e2="DDI-PubMed.17217399.s4.e7" /></sentence><sentence text=" None of the FQs changed Vmax, Km or intrinsic clearance (Vmax/Km) of MDZ"><entity charOffset="70-72" id="DDI-PubMed.17217399.s5.e0" text="MDZ" /></sentence><sentence text=" For in vivo test, we examined the effects of oral administration of EFX and OFX on the pharmacokinetics of quinidine (QN), a CYP3A substrate"><entity charOffset="108-117" id="DDI-PubMed.17217399.s6.e0" text="quinidine" /><entity charOffset="119-121" id="DDI-PubMed.17217399.s6.e1" text="QN" /><entity charOffset="69-70" id="DDI-PubMed.17217399.s6.e2" text="EFX" /><entity charOffset="77-78" id="DDI-PubMed.17217399.s6.e3" text="OFX" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e2" e2="DDI-PubMed.17217399.s6.e2" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e2" e2="DDI-PubMed.17217399.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e2" e2="DDI-PubMed.17217399.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e2" e2="DDI-PubMed.17217399.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e3" e2="DDI-PubMed.17217399.s6.e3" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e3" e2="DDI-PubMed.17217399.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e3" e2="DDI-PubMed.17217399.s6.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e0" e2="DDI-PubMed.17217399.s6.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s6.e0" e2="DDI-PubMed.17217399.s6.e1" /></sentence><sentence text=" EFX or OFX (10 mg/kg) was administered once a day for 3 days"><entity charOffset="1-3" id="DDI-PubMed.17217399.s7.e0" text="EFX" /><entity charOffset="8-10" id="DDI-PubMed.17217399.s7.e1" text="OFX" /><pair ddi="false" e1="DDI-PubMed.17217399.s7.e0" e2="DDI-PubMed.17217399.s7.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s7.e0" e2="DDI-PubMed.17217399.s7.e1" /></sentence><sentence text=" QN (2 mg/kg) was intravenously injected at 2 h after the final dose of FQs administration"><entity charOffset="1-3" id="DDI-PubMed.17217399.s8.e0" text="QN" /></sentence><sentence text=" The same dose of QN was intravenously injected 3 weeks before the start of FQs administration for control"><entity charOffset="18-19" id="DDI-PubMed.17217399.s9.e0" text="QN" /></sentence><sentence text=" Neither EFX nor OFX changed the pharmacokinetic parameters of QN"><entity charOffset="9-10" id="DDI-PubMed.17217399.s10.e0" text="EFX" /><entity charOffset="17-18" id="DDI-PubMed.17217399.s10.e1" text="OFX" /><entity charOffset="63-64" id="DDI-PubMed.17217399.s10.e2" text="QN" /><pair ddi="false" e1="DDI-PubMed.17217399.s10.e0" e2="DDI-PubMed.17217399.s10.e0" /><pair ddi="false" e1="DDI-PubMed.17217399.s10.e0" e2="DDI-PubMed.17217399.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s10.e0" e2="DDI-PubMed.17217399.s10.e2" /><pair ddi="false" e1="DDI-PubMed.17217399.s10.e1" e2="DDI-PubMed.17217399.s10.e1" /><pair ddi="false" e1="DDI-PubMed.17217399.s10.e1" e2="DDI-PubMed.17217399.s10.e2" /></sentence><sentence text=" These in vitro and in vivo consisted results suggest that these FQs lack the inhibitory effects on CYP3A activities in dogs" /><sentence text=" Hence, given these results, the risk of drug-drug interaction is unlikely to occur between FQs and CYP3A substrates in clinical situation in dogs" /><sentence text="" /></document>